Prerpints.org logo
Preprint
Communication

Impact of Feeding Vitamin D3 Encapsulated by Sulfur-Saturated Bovine Lactoferrin-Alginate Complex Coacervates Using Microbial Transglutaminase on the Immune Response of Late-Lactating Dairy Goats

Altmetrics

Downloads

143

Views

189

Comments

0

A peer-reviewed article of this preprint also exists.

Submitted:

17 April 2024

Posted:

18 April 2024

You are already at the latest version

Alerts
Abstract
Mastitis-causing bacteria can establish persistent infections in the mammary gland of commercially important dairy animals despite the presence of strong specific humoral and cellular immune mechanisms. The aim of this study was to encapsulate vitamin D3 by complex coacervation with sulfur-saturated bovine lactoferrin-alginate using microbial transglutaminase-catalyzed crosslinking and investigate the oral administration of encapsulated vitamin D3 in blood serum biomarkers of the immune response in late-lactating dairy goats. Dairy goats (n = 18) in late lactation were randomly assigned to three experimental groups (n = 6), after balancing weight. Dairy goats were orally administered with 0.35 mg vitamin D3/day in the unencapsulated form and 0.35 mg vitamin D3/day in the encapsulated powder form. Another group received the basal diet. The experimental period lasted 6 weeks. The blood serum concentrations of 25-hydroxyvitamin D3 [25-(OH)-D3], lactoferrin, immunoglobulin A (IgA), and interferon-gamma (INF-γ) were measured. The delivery of vitamin D3 to dairy goats resulted in a marked increase of 25-(OH)-D3 concentration in serum while the serum level of lactoferrin also increased. Alternatively, the serum levels of IgA and the immunomodulatory cytokine INF-γ were elevated following supplementation with the encapsulated vitamin D3. Overall, the capsules in the powder form used in this study kept vitamin D3 highly bioavailable.
Keywords: 
Subject: Biology and Life Sciences  -   Immunology and Microbiology

1. Introduction

Vitamin D3, which is formed in the skin or absorbed through the gastrointestinal tract, is modified by enzymatic hydroxylation to form first in the liver, 25-(OH)-D3, which is a plasma transport form of the vitamin, and then in the kidney to form 1,25-(OH)2D3, the active hormone, or 24,25-(OH)2D3 form of the vitamin and other derivatives. It appears that vitamin D3 stimulates active transport of calcium across mucosal cells of the small intestine [1]. Vitamin D3 also has a precise role in immunoregulation in response to microbial threat [2]. The protective effect of vitamin D3 on infectious diseases such as SARS-CoV-2 (Covid-19), tuberculosis, and mastitis has been linked to a direct interaction of vitamin D3 on cells of the immune system [3,4,5].
Vitamin D3 is often included in foods as dispersions in emulsified lipid carriers (e.g., milk), which provide an effective barrier against environmental stresses (e.g., oxidation). A variety of delivery systems have been developed to encapsulate bioactive compounds, and most are applicable to the encapsulation of lipid-soluble bioactive compounds [6].
Usually, encapsulation allows for even dispersion of bioactive compounds throughout the products, meaning consumers will get the same amount of a bioactive compound, such as vitamin D3 in each bite of food or sip of a drink [7]. Encapsulation also improves the shelf-life of products, thereby preventing vitamin D3 from degrading over time and keeping the formulation stable [7]. There are also the concerns of intestinal absorption of liposoluble bioactive compounds. Properly encapsulated liposoluble bioactive compounds such as vitamin D3 are thought to enter the bloodstream faster and in greater amounts [7] compared to the unencapsulated forms.
Protein-polysaccharide complex coacervates can be used as inexpensive encapsulation carriers for bioactive compounds in food and beverage products [8]. The coacervation encapsulation approach involves the processing steps of emulsification, coacervation, and shell formation and/or hardening [9]. Coacervation is a chemical method for producing biopolymer droplets in suspension based on the separation of two liquid phases into one concentrated colloidal phase [10]. Complex coacervation is the result of electrostatic interaction between two biopolymers with opposite charges, generally a protein and a polysaccharide [9]. Complex coacervates between whey proteins (e.g., bovine lactoferrin) and polysaccharides such as carboxymethylcellulose, pectin, and alginate have been recently used to encapsulate liposoluble bioactive compounds [11,12].
The use of cross-linking agents provides more resistant structures to capsules produced by colloidal complexation [13] or complex coacervation [14]. The coacervation encapsulation process may increase the absorption of bioactive compounds by controlled release [15].
The primary aim of this study was to specifically evaluate the immunomodulatory role of vitamin D3 encapsulated by sulfur-saturated bovine lactoferrin-alginate complex coacervates using microbial transglutaminase in late-lactating dairy goats. Ingestion of the vitamin D3 capsules may result in a marked and rapid increase in immunological responses for the prevention of bacterial invasion (e.g., mastitis) in the mammalian host.

2. Materials and Methods

Cholecalciferol (vitamin D3), methylsulfonylmethane, sodium alginate, and microbial transglutaminase were purchased from Sigma-Aldrich (St. Louis, MO, USA). The 25-hydroxyvitamin D3 [25-(OH)-D3] was purchased in crystalline form from Cayman Chemical (Ann Arbor, MI, USA). Medium-chain triglycerides (MCTs) oil (Neobee M-5, ≥ 66% C8:0 and ≥ 32% C10:0 content) was kindly donated by Stepan Company (Nortfield, IL, USA). Bovine lactoferrin-FD (10321412) was a gift from MDV International (Delhi, NY, USA), whose purity was more than 90% and 15.7 mg of iron/100 g of bovine lactoferrin. Bovine lactoferrin (2 g) was dissolved in 0.1 M sodium bicarbonate with methylsulfonylmethane (0.5 g) for 24 h at room temperature (20 °C), followed by extensive dialysis against sodium bicarbonate to remove ‘unbound’ sulfur ions and then the solution was freeze-dried (LABCONCO, Kansas City, MO, USA). Sulfur saturation of bovine lactoferrin with methylsulfonylmethane was 90.4% as determined by MACRO Cube Elemental Analyzer (Quantum Analytics, The Woodlands, TX, USA). The solvents used for the extraction and analysis of samples were HPLC-grade and purchased from Sigma-Aldrich. All other chemicals and reagents were of analytical-grade (Sigma-Aldrich). Deionized water, prepared by passing distilled water over a mixed bed cation-anion exchanger, was used throughout this study.
The protein and polysaccharide were prepared to contain a total concentration of 1.0% (w/w) and biopolymer mixing ratio of 9:1 (sulfur-saturated bovine lactoferrin:sodium alginate) in aqueous solution at pH 4.0. Vitamin D3, previously dispersed in warmed (37 °C) MCTs oil (0.75%, w/w) by a magnetic stirring hotplate (Thermo Fisher Scientific), was added to the aqueous solution (74.25%, w/w in the final emulsion) of sulfur-saturated bovine lactoferrin to give a concentration of 540 μg/mL vitamin D3 in the final emulsion, and pre-emulsified with a hand-held homogenizer (Biospec Products Inc., Bartlesville, OK, USA) at low speed for 3 min at 20 °C. The sodium alginate aqueous solution (25.0%, w/w in the final emulsion), previously acidified to pH 4.0 with acetic acid (20%, w/w), and the coarse emulsion was homogenized twice at 82.74 MPa (12,000 psi) at a temperature of 50 °C through a high-pressure TC5 homogenizer (Stansted Fluid Power, Harlow, U.K). The temperature of the oil-in-water emulsion was reduced to 5 °C using an ice-water bath for 60 min. Microbial transglutaminase solution (0.25%, w/w) was added under constant magnetic stirring (Thermo Fisher Scientific) at 400 rpm for 3 h at 25 °C to induce cross-linking. Immediately after treatment, microbial transglutaminase was inactivated by freezing the oil-in-water emulsion for 10 min. The vitamin D3 capsules were kept at 10 °C for 48 h, and then the supernatant was removed by decantation. The vitamin D3 capsules were frozen in liquid nitrogen and freeze-dried for 24 h. The quantitative determination of vitamin D3-loaded capsules was performed using HPLC-UV [16].
Encapsulation efficiency (EE%) of the vitamin D3 capsules was calculated as follows:
EE% = (Loaded vitamin D3/Total vitamin D3) x 100
The stability of vitamin D3-loaded capsules was evaluated during storage at 24 °C under nitrogen gas for a period of 6 months. Vitamin D3 content was measured at 1st, 5th, 10th, 15th days, 30th days, 60th days, 90 days, and 180 days. The content of vitamin D3 was determined by HPLC-UV [16].
In a 6-week feeding trial, eighteen American-bred, French-Alpine dairy goats (mean age 2.5 years, mean BW 114.2 kg) were selected from the milking herd of the International Goat Research Center at Prairie View A&M University, Prairie View, TX, USA. All experimental procedures with the goats were in strict compliance with the current guidelines and legal requirements established in the United States for the proper use and care of animals and approved by the Institutional Animal Care and Use Committee at Prairie View A&M University (Protocol # 2023-051). A total of six goats per experimental group (n = 18) were used. Our sample size also follows the recommendations of the Institutional Animal Care and Use Committee at Prairie View A&M University for discovery experiments where at least 4 biological replicates are needed.
The selected dairy goats were randomly assigned to three experimental groups: control (n =6), vitamin D3 supplementation (0.35 mg vitamin D3/day) in the unencapsulated form previously dispersed in MCTs oil (n = 6) and vitamin D3 supplementation (0.35 mg vitamin D3/day) in the encapsulated powder form (n= 6). After the initial 2 weeks of adjustment period, the experiment continued for 6 weeks. All goats were in late lactation (172 DIM; 1.06 L/day) and goats were randomly assigned to an individual feeding gate on the day of enrollment.
The treatment of dairy goats fed the encapsulated vitamin D3 consisted of 1 g of vitamin D3 capsules per goat (0.35 mg vitamin D3/day) in addition to the base ration that provided 0.05 mg of vitamin D3 daily. As a functional protein, sulfur-saturated bovine lactoferrin is an interesting biopolymeric wall system used to encapsulate vitamin D3. Thus, the treatment of the group of dairy goats fed the encapsulated vitamin D3 consisted of 1 g of the vitamin D3 capsules provided sulfur-saturated bovine lactoferrin (900 mg sulfur-saturated bovine lactoferrin/day). It should be noted here that the treatment group of dairy goats fed the encapsulated vitamin D3 consisted of 1 g vitamin D3 also provided a polysaccharide, sodium alginate (100 mg sodium alginate/day), used to encapsulate vitamin D3. A top-dress supplement for the treatment with the encapsulated vitamin D3 was prepared by mixing 1 g of the vitamin D3 capsules with cornmeal to provide 0.35 mg of vitamin D3, 900 mg of sulfur-saturated bovine lactoferrin, and 100 mg of sodium alginate in 100 g of total mixture. A top-dress supplement for the treatment with the unencapsulated vitamin D3 was prepared by combining vitamin D3 in MCTs oil (0.35 mg vitamin D3/5 mL of MCTs oil), homogenized for adequate dispersal, and mixed with cornmeal to provide 0.35 mg of vitamin D3 in 100 g of total mixture. The two top-dress supplements were not mixed into the ration and were consumed readily by all goats upon delivery.
The control animals received the basal diet without supplementation. The basal diet was composed of 69.3% oats, 1.35% soybean meal, 2.05% corn, 26.04% alfalfa meal, 0.93% cottonseed hulls, 0.31% dicalcium phosphate, and 0.06% vitamin A, D3, and E supplement. The experimental and the control animals were fed twice a day, in the morning and in the evenings. The animals were given 2.07 kg of either the control or the experimental diet twice a day, in the morning and evening and the leftovers were measured. The unencapsulated vitamin D3 and the encapsulated vitamin D3 were only added to the morning feeding as a top-dress. The feeding duration of this experiment was 6 weeks. Hay and water were available to animals ad libitum. Housing and care of the animals conformed to the approved institutional animal care and use committee practices and standards of the university.
Blood samples (5 mL) were collected by puncture of the jugular vein using siliconized needles (21 G x 1 in) with a vacuum system. The blood samples taken at 0 week and 6 weeks of treatment were transferred into 10-mLvacuum tube (serum separator tube) (Becton Dickinson Vacutainer Systems, Franklin Lakes, NJ, USA). Tubes were centrifuged at 3,500X g for 5 min in a refrigerated centrifuge (4 °C) for serum separation within 30 min of sample collection. Serum samples were transferred into microtubes using Pasteur pipettes. The samples were maintained at 2-8 °C and immediately analyzed, avoiding freeze-thaw cycles because this is detrimental to many serum components.
All serum analyses were performed in triplicate. Serum 25-(OH)-D3 concentrations were quantified using a CDC-certified LC-MS/MS method, which has been described in detail elsewhere [17]. Serum lactoferrin, IgA, and INF-γ concentrations were quantified using commercially available ELISA kits (Sigma-Aldrich), according to the manufacturer’s directions.

Statistical Analysis

Quantitative data for the combination of response and treatment variable are summarized with mean ± standard error. A paired t test under pre-posttest design was performed to compare the difference between before supplementation (week 0) and after supplementation (week 6) with animals assigned to different dietary groups. The outcome variables [25-(OH)-D3, lactoferrin, IgA, and INF-γ serum concentrations] are measured before and after the supplementation. The 5% significance level was applied to the paired t test. Experimental data were analyzed using SAS software (version 9.4, SAS Institute, Cary, NC, USA).

3. Results and Discussion

After loading vitamin D3 within the sulfur-saturated bovine lactoferrin-sodium alginate complex coacervates followed by transglutaminase crosslinking, the physicochemical properties of the encapsulated vitamin D3 delivery system such as encapsulation efficiency and storage stability were evaluated. The encapsulation of vitamin D3 attained a high encapsulation efficiency of 91.2%. The capsules contained vitamin D3 at a concentration of 0.35 mg per gram (0.035%) as determined by HPLC-UV [16]. As to the storage stability of the vitamin D3 capsules, there was little change in concentration after 3 months of storage at 24 °C, with a decrease in concentration of about 0.2%. Six months later, the storage stability decreased 1.3% at 24 °C, which was not significant. These results suggest that vitamin D3 loading in the complex coacervates of sulfur-saturated lactoferrin and sodium alginate with transglutaminase, as an effective protein cross-linker, have good stability.
The in vivo test performed on dairy goats confirmed the efficiency of the intake of encapsulated vitamin D3 (0.35 mg vitamin D3/day) in increasing the concentration of circulating 25-(OH)-D3 during late lactation (Table 1). Charoenngam and Holick in 2020 [18] noted that enhancing 25-(OH)-D3 status contributes to increased immunological vigor in humans. Merriman et al. in 2018 [19] found that intramammary 25-(OH)-D3 treatment directly influences immune cells of the mammary gland of lactating dairy cows in response to endotoxin-induced mastitis by increasing vitamin D3 signaling in mammary immune cells. Moreover, Poindexter et al. in 2020 [20] observed that feeding 25-(OH)-D3 to lactating dairy cows increased circulating 25-(OH)-D3, which appears to improve immune responses to intramammary Streptococcus uberis challenge, thereby protecting the mammary glands from mastitis. These nutritionally-induced changes observed by Poindexter et al. in 2020 [20] also occurred via vitamin D3 signaling. A dietary requirement for a source of preformed vitamin D3 (e.g., [25-(OH)-D3]) has been identified by Poindexter et al. in 2020 [20] as necessary for normal development of cellular immune responses of lactating dairy cows. Comparison of 25-hydroxyvitamin D3 [25-(OH)-D3] serum levels between baseline and supplementation (unencapsulated vitamin D3 vs. encapsulated vitamin D3) indicated significant (p < 0.0001) improvements in both supplemented groups (Table 1), but we observed a higher (p < 0.0001) 25-(OH)-D3 serum concentration at 6 weeks in dairy goats fed the encapsulated form of vitamin D3, compared with the serum concentration of dairy goats fed the unencapsulated form of vitamin D3, at 6 weeks (Table 1). This may be attributable to the efficacy of the delivery system.
Human lactoferrin is a natural whey protein that helps to fight and prevent infections and strengthens the body’s defense system [21]. This whey protein is present in substantial quantities in mother’s milk and plays an important role in the defense system of infants. This whey protein is also present in various body fluids and continues to play an important role against a wide range of infections [21]. Likewise, the consumption of bovine lactoferrin has been shown to support the immune and antioxidant status of healthy human males [22]. Studies in mice have demonstrated that the oral use of bovine lactoferrin increases immune function and resistance to infection [23]. In our study, we were looking at vitamin D3 (0.35 mg vitamin D3/day) encapsulated with sulfur-saturated bovine lactoferrin (900 mg sulfur-saturated bovine lactoferrin/day) and sodium alginate (100 mg sodium alginate/day) to see if it could enhance the immune response of dairy goats at late-lactating stages. We observed that supplementation with the encapsulated vitamin D3 significantly (p < 0.0001) increases the serum levels of lactoferrin compared to the group of dairy goats that were fed the unencapsulated vitamin D3 (Table 1). The sulfur-saturated bovine lactoferrin, was used as a biopolymeric wall system to encapsulate vitamin D3 that contributes to immune regulation in lactating dairy goats by maintaining the circulation of IgA in late lactation at high concentration compared to the experimental group of dairy goats fed the unencapsulated vitamin D3 (Table 1). Lactoferrin should in theory exert advantageous immunomodulatory effect because it can pass through the blood/milk barrier, thereby protecting the mammary gland from bacterial invasion [24]. In the experimental group of dairy goats that were fed the encapsulated vitamin D3, the serum levels of IgA were significantly (p < 0.0001) increased (Table 1). Lactoferrin has been identified as a critical nutrient and the combination of lactoferrin and IgA is particularly important for infants, whose immune systems are still developing. Breast milk contains high levels of both lactoferrin and IgA, which help to protect infants against infections [25].
As noted, 25-(OH)-D3 is a precursor to the active form of vitamin D3, which is a hormone that plays a vital role in many bodily functions, including immune regulation [26]. The oral intake of vitamin D3 or preformed vitamin D3 [25-(OH)-D3] has been shown to work together with lactoferrin to boost immune function even more effectively than either one alone among those individuals who were affected by exposure to SARS-COV-2 infection [27]. Moreover, high serum levels of INF-γ, an immunomodulatory cytokine, are associated with a stronger immune response and improved protection against infection [28]. INF-γ production was markedly higher (p < 0.0001) in blood serums obtained from the dairy goats fed the encapsulated vitamin D3 (0.35 mg vitamin D3/day) than from the group of dairy goats fed the unencapsulated vitamin D3 (0.35 mg vitamin D3/day) (Table 1). This observation suggests that the consumption of encapsulated vitamin D3 may be associated with an improved immune defense.

4. Conclusions

Hence, we are reporting evidence that an increased uptake of vitamin D3 in late-lactating dairy goats supplemented with the encapsulated vitamin D3 has occurred. We have shown that a total vitamin D3 intake of 0.35 mg vitamin D3/day as encapsulated vitamin D3 is sufficient to maintain 25-(OH)-D3 concentrations > 50 ng/mL. Additionally, serum levels of IgA and INF-γ were also significantly (p < 0.0001) increased. We speculate that the sulfur-saturated bovine lactoferrin (900 mg sulfur-saturated bovine lactoferrin/day) used in this study as a biopolymer to encapsulate vitamin D3 stimulates IgA release in serum. Such sulfur-saturated bovine lactoferrin works synergistically with serum 25-(OH)-D3 to boost the immune response as evidenced by the high serum levels of INF-γ. Our data, apart from indicating bioavailability to vitamin D3, indicates that sulfur-saturated lactoferrin is a possible alternative for commercial bovine lactoferrin in freeze-dried lactoferrin-polysaccharide systems.

Author Contributions

Conceptualization, A.M.-G; methodology, A.M.-G; formal analysis, A.M.-G., M.T.N.d.G., S.W., Y.J.; investigation, A.M.-G.; data curation, A.M.-G., M.T.N.d.G.; writing—original draft preparation, A.M.-G; writing—review and editing, A.M.-G., M.T.N.d.G., R.A. ; visualization, M.T.N.d.G.; supervision, A.M.-G.; project administration, A.M.-G.; funding acquisition, A.M.-G. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the U.S. Department of Agriculture’s National Institute of Food and Agriculture (NIFA) competitive grant (Grant No. 2023-67018-39181, Funding Program: Food Safety and Defense, A1332), and by Evans-Allen, the intramural research program.

Institutional Review Board Statement

The study was conducted in strict compliance with the current guidelines and legal requirements established in the United States for the proper use and care of animals and approved by the Institutional Animal Care and Use Committee of Prairie View A&M University (Protocol # 2023-051).

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are available on request from the corresponding author.

Acknowledgments

We acknowledge the administrative support of Executive Research Director Erdogan Memili.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Fleet, J.C. Vitamin D-mediated regulation of intestinal calcium absorption. Nutrients 2022, 14, 3351. [Google Scholar] [CrossRef] [PubMed]
  2. Ismailova, A.; White, J.H. Vitamin D, infections and immunity. Rev. Endocr. Metab. Disord. 2022, 23, 265–277. [Google Scholar] [CrossRef] [PubMed]
  3. Argano, C.; Mallaci Bocchio, R.; Natoli, G.; Scibetta, S.; Lo Monaco, M.; Corrao, S. Protective effect of vitamin D supplementation on COVID-19-related intensive care hospitalization and mortality: Definitive evidence from meta-analysis and trial sequential analysis. Pharmaceuticals 2023, 16, 130. [Google Scholar] [CrossRef] [PubMed]
  4. Papagni, R.; Pellegrino, C.; Di Gennaro, F.; Patti, G.; Ricciardi, A.; Novara, R.; Cotugno, S.; Musso, M.; Guido, G.; Ronga, L.; Stolfa, S.; Bavaro, D.F.; Romanelli, F.; Totaro, V.; Lattanzio, R.; De laco, G.; Palmieri, F.; Saracino, A.; Gualano, G. Impact of vitamin D in prophylaxis and treatment in tuberculosis patients. Int. J. of Mol. Sci. 2022, 23, 3860. [Google Scholar] [CrossRef] [PubMed]
  5. Zemanova, M.; Langova, L.; Novotná, I.; Dvorakova, P.; Vrtkova, I.; Havlicek, Z. Immune mechanisms, resistance genes, and their roles in the prevention of mastitis in dairy cows. Arch. Anim. Breed. 2022, 65, 371–384. [Google Scholar] [CrossRef] [PubMed]
  6. Banasaz, S.; Morozova, K.; Ferrentino, G.; Scampicchio, M. Encapsulation of lipid-soluble bioactives by nanoemulsions. Molecules 2020, 25, 3966. [Google Scholar] [CrossRef] [PubMed]
  7. Yan, C.; Kim, S-R. ; Ruiz, D.R; Farmer, J.R. Microencapsulation for food applications: A review. ACS Appl. Bio Mater. 2022, 5, 5497–5512. [Google Scholar] [CrossRef] [PubMed]
  8. Devi, N.; Sarmah, M.; Khatun, B.; Maji, T.K. Encapsulation of active ingredients in polysaccharide-protein complex coacervates. Adv. Colloid Interface Sci. 2017, 239, 136–145. [Google Scholar] [CrossRef] [PubMed]
  9. Zhang, H.; Fu, Y.; Xu, Y.; Niu, F.; Li, Z.; Ba, C.; Jin, B.; Chen, G.; Li, X. One-step assembly of zein/caseinate/alginate nanoparticles for encapsulation and improved bioaccessibility of propolis. Food Funct. 2019, 10, 635–645. [Google Scholar] [CrossRef]
  10. Sing, C.E.; Perry, S.L. Recent progress in the science of complex coacervation. Soft Matter 2020, 16, 2885–2914. [Google Scholar] [CrossRef]
  11. Bastos, L.P.H.; dos Santos, C.H.C.; de Carvalho, M.G.; Garcia-Rojas, E.E. Encapsulation of the black pepper (Piper nigrum L.) essential oil by lactoferrin-sodium alginate complex coacervates: Structural characterization and simulated gastrointestinal conditions. Food Chem. 2020, 316, 126345. [Google Scholar] [CrossRef]
  12. Rojas-Moreno, S.; Osorio-Revilla, G.; Gallardo-Velázquez, T.; Cárdenas-Bailón, F.; Meza-Márquez, G. Effect of the cross-linking agent and drying method on encapsulation efficiency of orange essential oil by complex coacervation using whey protein isolate with different polysaccharides. J. Microencapsul. 2018, 35, 165–180. [Google Scholar] [CrossRef] [PubMed]
  13. Mora-Gutierrez, A.; Attaie, R.; Kirven, J.M.; Farrell Jr., H. M. Cross-linking of bovine and caprine caseins by microbial transglutaminase and their use as microencapsulating agents for n-3 fatty acids. Int. J. Food Sci. Technol. 2014, 49, 1530–1543. [Google Scholar] [CrossRef]
  14. Joye, I.J.; McClements, D.J. Biopolymer-based delivery systems: Challenges and opportunities. Curr. Top. Med. Chem. 2016, 16, 1026–1039. [Google Scholar] [CrossRef] [PubMed]
  15. Timilsena, Y.P.; Haque, Md.A.; Adhikari, B. Encapsulation in the food industry: A brief historical overview to recent developments. Food Nutr. Sci. 2020, 11, 481–508. [Google Scholar] [CrossRef]
  16. Temova, Ž.; Roŝcar, R. Stability-indicating HPLC-UV method for vitamin D3 determination in solutions, nutritional supplements and pharmaceuticals. J. Chromatogr. Sci. 2016, 54, 1180–1186. [Google Scholar] [CrossRef] [PubMed]
  17. Kiely, M.E.; Zhang, J.Y.; Kinsella, M.; Khashan, A.S.; Kenny, L.C. Vitamin D status is associated with uteroplacental dysfunction indicated by pre-eclampsia and small-for-gestational-age birth in a large prospective pregnancy cohort in Ireland with low vitamin D status. Am. J. Clin. Nutr. 2016, 104, 354–361. [Google Scholar] [CrossRef] [PubMed]
  18. Charoenngam, N.; Holick, M.F. Immunologic effects of vitamin D on human health and disease. Nutrients 2020, 12, 2097. [Google Scholar] [CrossRef] [PubMed]
  19. Merriman, K.; Powell, J.L.; Santos, J.E.P.; Nelson, C.D. Intramammary 25-hydroxyvitamin D3 treatment modulates innate immune responses to endotoxin-induced mastitis. J. Dairy Sci. 2018, 101, 7593–7607. [Google Scholar] [CrossRef]
  20. Poindexter, M.B.; Kweh, M.F.; Zimpel, R.; Zuniga, J.; Lopera, C.; Zenobi, M.G.; Jiang, Y.; Engstrom, M.; Celi, P.; Santos, J.E.P.; Nelson, C.D. Feeding supplemental 25-hydroxyvitamin D3 increases serum mineral concentrations and alters mammary immunity of lactating dairy cows. J. Dairy Sci. 2020, 103, 805–822. [Google Scholar] [CrossRef]
  21. Sisqueiros-Cendόn, T.; Arévalo-Gallegos, S.; Iglesias-Figueroa, B.F.; García-Montoya, I.A.; Salazar-Martínez, J.; Rascόn-Cruz, Q. Immunomodulatory effects of lactoferrin. Acta Pharmacol. Sin. 2014, 35, 557–566. [Google Scholar] [CrossRef] [PubMed]
  22. Mulder, A.M.; Connellan, P.A.; Oliver, C.J.; Morris, C.A.; Stevenson, L.V. Bovine lactoferrin supplementation supports immune and antioxidant status in healthy human males. Nutr. Res. 2008, 28, 583–589. [Google Scholar] [CrossRef] [PubMed]
  23. Drago-Serrano, M.E.; Rivera-Aguilar, V.; Reséndiz-Albor, A.A.; Campos-Rodriguez, R. Lactoferrin increases both resistance to Salmonella typhimurium infection and the production of antibodies in mice. Immunol. Lett. 2010, 134, 35–46. [Google Scholar] [CrossRef] [PubMed]
  24. Shao, Y.; Zhang, X.; Zhang, H.; Tian, B.; Weng, Y.; Huang, J.; Lu, C.D.; Shi, H. Effects of dietary supplementation of bovine lactoferricin on rumen microbiota, lactation, and health in dairy goats. Front. Nutr. 2021, 8, 722303. [Google Scholar] [CrossRef] [PubMed]
  25. Metha, R.; Petrova, A. Biologically active breast milk proteins in association with very preterm delivery and stage of lactation. J. Perinatol. 2011, 31, 58–62. [Google Scholar] [CrossRef] [PubMed]
  26. Szymczak, I.; Pawliczak, R. The active metabolite of vitamin D3 as a potential immunomodulator. Scand. J. Immunol. 2016, 83, 83–91. [Google Scholar] [CrossRef] [PubMed]
  27. Cipriano, M.; Ruberti, E.; Tovani-Palone, M.R. Combined use of lactoferrin and vitamin D as a preventive and therapeutic supplement for SARS-CoV-2 infection: Current evidence. World J. Clin. Cases 2022, 10, 11665–11670. [Google Scholar] [CrossRef]
  28. Kak, G.; Raza, M.; Tiwari, B.K. Interferon-gamma (IFN-γ): Exploring its implications in infectious diseases. Biomol. Concepts 2018, 9, 64–79. [Google Scholar] [CrossRef]
Table 1. Serum concentrations showing significant differences in 25-hydroxyvitamin D3 [25-(OH)-D3], lactoferrin, immunoglobulin A (IgA), and interferon-gamma (INF-γ) at baseline (0 week) and at feeding period (6 weeks) between dietary groups1,2.
Table 1. Serum concentrations showing significant differences in 25-hydroxyvitamin D3 [25-(OH)-D3], lactoferrin, immunoglobulin A (IgA), and interferon-gamma (INF-γ) at baseline (0 week) and at feeding period (6 weeks) between dietary groups1,2.
Item Baseline (0 week) Feeding period (6 weeks) p-Value
25-(OH)-D3 (ng/mL)
Treatment U 25.92 ± 1.63 39.10 ± 1.53 <0.0001
Treatment E 27.30 ± 0.93 51.37 ± 1.27 <0.0001
Control 23.53 ± 0.78 24.35 ± 1.29 0.500
Lactoferrin (μg/mL)
Treatment U 148.28 ± 1.03 149.60 ± 3.51 0.728
Treatment E 146.90 ± 1.32 228.40 ± 4.54 <0.0001
Control 147.08 ± 1.27 146.60 ± 0.75 0.723
IgA (μg/mL)
Treatment U 430.12 ± 3.57 425.27 ± 5.10 0.547
Treatment E 427.72 ± 5.70 576.62 ± 2.01 <0.0001
Control 428.15 ± 4.75 426.61 ± 1.83 0.763
INF-γ (pg/mL)
Treatment U 36.33 ± 3.48 39.23 ± 4.13 0.701
Treatment E 35.17 ± 2.49 62.08 ± 2.00 <0.0001
Control 32.27 ± 2.40 36.81 ± 2.16 0.807
1 Dairy goats in late lactation fed a basal diet (control group), a basal diet supplemented with the unencapsulated form of vitamin D3 (treatment group U), and a basal diet supplemented with the encapsulated form of vitamin D3 (treatment group E). 2 Data are presented as mean ± standard error; n = 18.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated